Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects.
The combined treatment approach—known as chemoradiation—was tested in 360 patients with muscle-invasive bladder cancer, a potentially deadly form of the disease. Results from the randomized phase III study appeared in the April 19 New England Journal of Medicine. Read more > >
A MESSAGE TO READERS
How Does NCI Fund Grant Applications?
In the 2011 fiscal year, NCI received 4,477 applications for R01 research grants, of which 652 (or approximately 15 percent) received funding. R01 grants are the most common type of NIH research grant. View charts and a table summarizing the overall funding patterns for R01 and R21 grants in various categories of investigators online.
- FDA Approves New Drug for Advanced Soft Tissue Sarcoma
- NCI Report Features Cancer Statistics through 2009
- Cyber-Seminar Will Explore How to Sustain Community Public Health Programs
- NCI Experts Contribute to HBO's "The Weight of the Nation" Documentary
- Free Workshop for Cancer Survivors: Recapturing Joy and Finding Meaning
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.